Henrui Pharmaceutical has received approval from China's National Medical Products Administration to conduct clinical trials for its HRS-3005 tablets. This innovative anti-tumor drug, developed in-house, is intended for use in B-cell malignant tumors. Currently, no similar drugs have been approved globally, and the project has incurred approximately 26.2 million yuan in R&D investment. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON Clinical trial approval for a novel drug. [lever_c_demoted from research: ic=1 ai=0.1]